# MiNK Therapeutics, Inc. (INKT)

> Source: Nexqual · https://nexqual.com/INKT · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, MiNK Therapeutics, Inc. (INKT), nexqual.com/INKT" · informational, not investment advice.

**Price:** USD 10.71 (+6.46% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 10.06 · day 10.18–11.52 · 52w 8.48–16.93 · market cap $54.7M · NCM

## Key facts
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $92K; 2 not under a Rule 10b5-1 plan ($92K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 42.5 (range 35–50).
- Total return with dividends: 1Y -28.5% vs S&P 500 +13.4%; 5Y -94.0% vs S&P 500 +76.9%.
- Next earnings: 2026-11-12, EPS estimate USD -0.5, revenue estimate $875K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$28.4M | -$30.9M | -$22.9M | -$11.3M | -$12.6M | -$12.0M |
| Net income | -$30.2M | -$28.0M | -$22.5M | -$10.8M | -$12.5M | -$11.4M |
| EPS (diluted) | -$11.60 | -$8.30 | -$6.54 | -$2.86 | -$2.93 | — |
| Free cash flow | -$13.1M | -$19.1M | -$15.8M | — | — | — |
| Cash + short-term investments | $38.9M | $19.6M | $3.4M | $4.6M | $13.4M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
Earnings yield -20.79%

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Buell Jennifer | Chief Executive Officer | 6,938 | $73K | 8.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04 | Ryan Barbara | Director | 1,500 | $19K | 6.4% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 42.5 (low 35, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | B. Riley Securities | Target raised | Buy | $43 → $50 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -28.5% | -94.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -28.6% | -43.1% |
| Volatility (annualized) | 71.5% | 143.5% |
| Max drawdown | -42.8% (Oct 2025→Mar 2026) | -97.4% (Nov 2021→Dec 2024) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 303.53 -1.39% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 89.27 -1.79% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.09 -0.35% · PRAX (Praxis Precision Medicines, Inc) USD 252.96 -2.30% · IONS (Ionis Pharmaceuticals, Inc.) USD 42.93 -2.23% · ABVX (Abivax SA) USD 88.01 -2.46%

## More
Full page: https://nexqual.com/INKT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in INKT's own 10-K filed 2026-03-31 (https://www.sec.gov/Archives/edgar/data/1840229/000119312526134813/inkt-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | AGENUS INC (AGEN) | "Our Intellectual Property Assignment and License Agreement with Agenus(September 2021), providing access to a portfolio of immuno-oncology assets and adjuvants to support combination strategies." |
| Competitor | Johnson & Johnson (JNJ) | "Key competitors developing autologous CAR-T and TCR-based therapies include large pharmaceutical and biotechnology companies such as Bristol-Myers Squibb (including former Celgene and Juno Therapeutics assets), Gilead Sc…" |

Other companies that name INKT in their own reports (relationship from INKT's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | AGENUS INC (AGEN) | 10-K 2026-03-16 | "Furthermore, our ability to generate cash from operations is dependent in part on the success of our licensees and collaboration partners, as well as the likelihood and timing of new strategic licensi…" |

## Company outlook (8-K filed 2026-08-13)

- "Additional data are expected in early 2027."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.50 | $-0.63 | -20.6% | $875,000 | 2 |
| Next quarter (ends 2026-12-31) | $-0.51 | $-0.66 | -22.7% | $1.0M | 2 |
| Current fiscal year (ends 2026-12-31) | $-2.21 | $-2.46 | -10.4% | $1.9M | 2 |
| Next fiscal year (ends 2027-12-31) | $-2.19 | $-2.85 | -23.3% | $2.8M | 2 |